Here the authors report a novel adiponectin-based dual agonist for adiponectin receptors 1 and 2 with a longer half-life, and show that it ameliorates NASH and liver fibrosis in mouse models. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatohepatitis.